Lung Cancer — Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer
Citation(s)
Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer